NCT00783549View on ClinicalTrials.gov

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 4, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Dyslipidaemias
Interventions
DRUG

an undetermined dose of GSK1292263

GSK investigational product or placebo

DRUG

ascending dose of GSK1292263

Ascending dose based on target exposures or placebo

DRUG

ascending dose of GSK1292263

An ascending dose based on target exposure

DRUG

ascending dose of GSK1292263

An ascending dose based on target exposures.

DRUG

ascending dose of GSK1292263

An ascending dose based on target exposure

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00783549 - A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs. | Biotech Hunter | Biotech Hunter